Arana Therapeutics Limited, (AIM: AAHx ASX: AAH) (the "Company"), the Australian
biopharmaceutical company that uses superior technology to develop next
generation drugs that will improve the lives of patients with inflammatory
diseases and cancer has today announced that it had received the remaining funds
of A$17.7 million arising from the sale of its shareholding in Domantis Ltd in
January 2007.
